Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.
Donna M EvonJ AmadorP StewartB B ReeveA S LokR K SterlingA M Di BisceglieN ReauMarina SerperSouvik SarkarJoseph K LimC E GolinM W FriedPublished in: Alimentary pharmacology & therapeutics (2018)
The psychometric properties of the HIT-6 and PROMIS measures performed satisfactorily in this large cohort of patients with HCV starting direct acting antiviral therapy. Opportunities exist for further refinement of these PROs. Evaluation of performance over time and in under-represented subgroups is needed.